| Dr David Lance Jackson, MD | |
|
3529 Fortuna Dr, Akron, OH 44312-5282 | |
| (330) 644-0022 | |
| (330) 644-0328 |
| Full Name | Dr David Lance Jackson |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 38 Years |
| Location | 3529 Fortuna Dr, Akron, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659473791 | NPI | - | NPPES |
| 0686066 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OH-35055410 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Akron General Medical Center | Akron, OH | Hospital |
| Summa Health System | Akron, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Partners Physician Group | 4183529340 | 488 |
News Archive
Scientists in the United States say they have discovered a part of the brain responsible for the feeling of deja vu.
Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.
OriGene Technologies, Inc., a leading gene-centric life sciences company, and the Institute for Systems Biology (ISB), announce plans to create a proteotypic PeptideAtlas and develop an SRM/MRM (single reaction monitoring, multiple reaction monitoring) mass spectrometry standard database for 5,000 human proteins. The new collaboration will apply ISB's novel systems biology mass spectrometry expertise to OriGene's large collection of full length human proteins.
Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.
› Verified 9 days ago
| Entity Name | Partners Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841239274 PECOS PAC ID: 4183529340 Enrollment ID: O20031202000183 |
News Archive
Scientists in the United States say they have discovered a part of the brain responsible for the feeling of deja vu.
Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.
OriGene Technologies, Inc., a leading gene-centric life sciences company, and the Institute for Systems Biology (ISB), announce plans to create a proteotypic PeptideAtlas and develop an SRM/MRM (single reaction monitoring, multiple reaction monitoring) mass spectrometry standard database for 5,000 human proteins. The new collaboration will apply ISB's novel systems biology mass spectrometry expertise to OriGene's large collection of full length human proteins.
Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.
› Verified 9 days ago
| Entity Name | South Central Family Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861571176 PECOS PAC ID: 4486813912 Enrollment ID: O20120301000915 |
News Archive
Scientists in the United States say they have discovered a part of the brain responsible for the feeling of deja vu.
Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.
OriGene Technologies, Inc., a leading gene-centric life sciences company, and the Institute for Systems Biology (ISB), announce plans to create a proteotypic PeptideAtlas and develop an SRM/MRM (single reaction monitoring, multiple reaction monitoring) mass spectrometry standard database for 5,000 human proteins. The new collaboration will apply ISB's novel systems biology mass spectrometry expertise to OriGene's large collection of full length human proteins.
Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Lance Jackson, MD 3529 Fortuna Dr, Akron, OH 44312-5282 Ph: (330) 644-0022 | Dr David Lance Jackson, MD 3529 Fortuna Dr, Akron, OH 44312-5282 Ph: (330) 644-0022 |
News Archive
Scientists in the United States say they have discovered a part of the brain responsible for the feeling of deja vu.
Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.
OriGene Technologies, Inc., a leading gene-centric life sciences company, and the Institute for Systems Biology (ISB), announce plans to create a proteotypic PeptideAtlas and develop an SRM/MRM (single reaction monitoring, multiple reaction monitoring) mass spectrometry standard database for 5,000 human proteins. The new collaboration will apply ISB's novel systems biology mass spectrometry expertise to OriGene's large collection of full length human proteins.
Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.
› Verified 9 days ago
Leon L. Zhong, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-4000 | |
Dr. Adarsh E Krishen, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 444 W Exchange St, Akron, OH 44302 Phone: 234-417-7630 | |
Dr. Lynn M Hamrich, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 55 Arch St Ste 3a, Akron, OH 44304 Phone: 330-375-3584 Fax: 234-312-2307 | |
James Jude Brown, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 5147 Manchester Rd, Akron, OH 44319 Phone: 330-644-3747 Fax: 330-644-9815 | |
Mr. William Kevin Lonsdorf, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2818 S Arlington Rd, Akron, OH 44312 Phone: 330-645-0148 Fax: 330-645-1524 | |
Trisha Imhoff, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 55 Arch St, Suite 3a, Akron, OH 44304 Phone: 330-375-3584 | |
Dr. Cynthia Link Weinstein, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 525 N Cleveland Massillon Rd, Suite 203, Akron, OH 44333 Phone: 330-666-9769 Fax: 330-666-7530 |